Hims & Hers Health (NYSE:HIMS - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.
Several other brokerages also recently commented on HIMS. Deutsche Bank increased their price objective on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a "hold" rating in a research note on Tuesday, August 11th. TD Cowen upped their price target on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a "hold" rating in a report on Tuesday, August 11th. Truist Financial upped their price target on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a "hold" rating in a report on Monday, August 24th. Morgan Stanley dropped their price target on Hims & Hers Health from $28.00 to $25.00 and set an "equal weight" rating for the company in a research note on Tuesday, November 10th. Finally, JPMorgan Chase & Co. started coverage on Hims & Hers Health in a report on Friday, September 11th. They set a "neutral" rating and a $32.00 price objective on the stock. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $30.80.
Get Our Latest Research Report on HIMS
Hims & Hers Health Stock Performance
NYSE:HIMS opened at $14.57 on Friday. The company has a market cap of $3.42 billion, a price-to-earnings ratio of -17.55 and a beta of 2.53. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $40.99. The company has a debt-to-equity ratio of 3.85, a quick ratio of 0.84 and a current ratio of 0.92. The stock has a fifty day moving average price of $26.51 and a 200-day moving average price of $26.43.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.06 by ($0.03). Hims & Hers Health had a negative return on equity of 9.62% and a negative net margin of 6.65%. The company had revenue of $890.37 million during the quarter, compared to the consensus estimate of $893.13 million. During the same quarter in the previous year, the business posted $0.06 EPS. The firm's revenue for the quarter was up 48.6% on a year-over-year basis. As a group, equities analysts anticipate that Hims & Hers Health will post -0.38 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, insider Deborah Autor sold 23,828 shares of the company's stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $18.53, for a total transaction of $441,532.84. Following the sale, the insider owned 48,961 shares in the company, valued at $907,247.33. This represents a 32.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total value of $398,226.53. Following the completion of the sale, the chief operating officer owned 456,660 shares of the company's stock, valued at approximately $12,964,577.40. The trade was a 2.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,041 shares of company stock valued at $2,764,840 over the last 90 days. 11.76% of the stock is owned by company insiders.
Institutional Trading of Hims & Hers Health
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. American Century Companies Inc. lifted its holdings in Hims & Hers Health by 129.0% during the 3rd quarter. American Century Companies Inc. now owns 76,401 shares of the company's stock worth $2,276,000 after purchasing an additional 43,045 shares in the last quarter. PCM Encore LLC purchased a new stake in shares of Hims & Hers Health in the third quarter worth about $266,000. Kestra Advisory Services LLC boosted its position in shares of Hims & Hers Health by 22.3% in the third quarter. Kestra Advisory Services LLC now owns 20,900 shares of the company's stock valued at $623,000 after acquiring an additional 3,811 shares during the period. Robinhood Markets Inc. bought a new position in shares of Hims & Hers Health in the third quarter valued at approximately $3,025,000. Finally, Allworth Financial LP grew its stake in Hims & Hers Health by 31.2% during the third quarter. Allworth Financial LP now owns 5,547 shares of the company's stock valued at $165,000 after acquiring an additional 1,318 shares in the last quarter. 63.52% of the stock is owned by institutional investors.
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.